Altamira Therapeutics Ltd. (CYTO) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Jul 3Jul 9Jul 14Feb 10Mar 10Mar 13Mar 18Mar 23

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

1.7x

Market Cap

$147300.00

MomentumView details →

1D Return

+0.00%

YTD Return

—

RSI (14)

73.1

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

1.7x

Market Cap

$147300.00

RSI (14)

73.1

MomentumView details →

1D Return

+0.00%

YTD Return

—

ProfitabilityView details →

Gross Margin

195.66%

Net Margin

4479.11%

EBITDA Margin

−571.73%

ROE (TTM)

867.88%

ROA (TTM)

−255.24%

Asset Turnover

−0.06x

GrowthView details →

Revenue YoY

—

EPS YoY

−15.66%

FCF YoY

+13.25%

Revenue CAGR 3Y

−100.00%

EPS CAGR 3Y

+97.46%

EBITDA YoY

+127.77%

EarningsView details →

EPS (Actual)

−$1.99

EPS Surprise

16.60%

Beats (12Q)

1/12

Next Q EPS Est

—

Avg Surprise (4Q)

−369.39%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

−1.90x

Current Ratio

0.32x

Quick Ratio

0.27x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

−353530.00

Net Income (TTM)

−15.84M

Op. CF (TTM)

−10.81M

Latest newsMore news →

No recent news for CYTO.

Similar companies

Humacyte, Inc.HUMAW OSR Holdings, Inc.OSRHW Jasper Therapeutics, Inc.JSPRW SAB Biotherapeutics, Inc.SABSW Instinct Bio Technical Company Holdings Inc. WarrantsBIOTW NRx Pharmaceuticals, Inc.NRXPW Find similar companies →

Latest newsMore news →

No recent news for CYTO.